

## ITEM 6. SELECTED FINANCIAL DATA

(In thousands, except per share data)

On November 3, 2008, we entered into a series of agreements with Acusphere, Inc. that resulted in Acusphere issuing to us a \$15 million senior secured convertible note, convertible into, among other potential options, a controlling interest in Acusphere; we also acquired license rights to certain Acusphere intellectual property in exchange for \$5 million plus future royalty payments. On March 28, 2008 we acquired certain intellectual property from Acusphere in exchange for \$10 million. We have determined that, as a result of these transactions, Acusphere is a variable interest entity and we are the primary beneficiary. As a result, we have consolidated Acusphere's results in accordance with FIN 46R, "Consolidation of Variable Interest Entities" ("FIN 46R"), as of November 3, 2008.

We completed the acquisitions of AMRIX® in August 2007, the issued share capital of Zeneus Holdings Limited on December 22, 2005, substantially all assets related to the TRISENOX® (arsenic trioxide) injection business from CTI and CTI Technologies, Inc., a wholly-owned subsidiary of CTI on July 18, 2005, outstanding capital stock of Salmedix, Inc. on June 14, 2005 and the outstanding shares of capital stock of CIMA LABS on August 12, 2004. These acquisitions have been accounted for either as business combinations or asset purchases.

### Five-year summary of selected financial data:

| Statement of operations data  | Year Ended December 31, |                              |                              |                              |                              |
|---|-------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|   | 2008                    | As Adjusted<br>2007*         | As Adjusted<br>2006*         | As Adjusted<br>2005*         | As Adjusted<br>2004*         |
| Sales . . . . .   | \$1,943,464             | \$1,727,299                  | \$1,720,172                  | \$1,156,518                  | \$ 980,375                   |
| Other revenues . . . . .  | 31,090                  | 45,339                       | 43,897                       | 55,374                       | 35,050                       |
| Total revenues . . . . .  | <u>1,974,554</u>        | <u>1,772,638</u>             | <u>1,764,069</u>             | <u>1,211,892</u>             | <u>1,015,425</u>             |
| Settlement reserve . . . . .  | 7,450                   | 425,000                      | —                            | —                            | —                            |
| Impairment charges . . . . .  | 99,719                  | —                            | 12,417                       | 20,820                       | 30,071                       |
| Acquired in-process research and development . . .                                  | 41,955                  | —                            | 5,000                        | 366,815                      | 185,700                      |
| Debt exchange expense . . . . .   | —                       | —                            | 48,122                       | —                            | 28,230                       |
| Write-off of deferred debt issuance costs . . . . .                                 | —                       | —                            | 13,105                       | 27,109                       | —                            |
| Restructuring charge . . . . .  | 8,415                   | —                            | —                            | —                            | —                            |
| Loss on sale of equipment . . . . .   | 17,178                  | 1,022                        | —                            | —                            | —                            |
| Income tax expense (benefit) . . . . .  | (20,665)                | 121,882                      | 94,419                       | (68,870)                     | 45,141                       |
| Loss attributable to minority interest . . . . .                                    | 21,073                  | —                            | —                            | —                            | —                            |
| Net income (loss) . . . . .   | <u>\$ 222,548</u>       | <u>\$ (194,125)</u>          | <u>\$ 146,509</u>            | <u>\$ (172,723)</u>          | <u>\$ (74,654)</u>           |
| Basic income (loss) per common share . . . . .                                      | <u>\$ 3.27</u>          | <u>\$ (2.91)</u>             | <u>\$ 2.42</u>               | <u>\$ (2.98)</u>             | <u>\$ (1.32)</u>             |
| Weighted average number of common shares<br>outstanding . . . . .                   | <u>68,018</u>           | <u>66,597</u>                | <u>60,507</u>                | <u>58,051</u>                | <u>56,489</u>                |
| Diluted income (loss) per common share . . . . .                                    | <u>\$ 2.92</u>          | <u>\$ (2.91)</u>             | <u>\$ 2.10</u>               | <u>\$ (2.98)</u>             | <u>\$ (1.32)</u>             |
| Weighted average number of common shares<br>outstanding-assuming dilution . . . . . | <u>76,097</u>           | <u>66,597</u>                | <u>69,672</u>                | <u>58,051</u>                | <u>56,489</u>                |
|   |                         |                              | <b>December 31,</b>          |                              |                              |
| <b>Balance sheet data</b>   | <b>2008</b>             | <b>As Adjusted<br/>2007*</b> | <b>As Adjusted<br/>2006*</b> | <b>As Adjusted<br/>2005*</b> | <b>As Adjusted<br/>2004*</b> |
| Cash, cash equivalents and investments . . . . .                                    | \$ 524,459              | \$ 826,265                   | \$ 521,724                   | \$ 484,090                   | \$ 791,676                   |
| Total assets . . . . .  | 3,169,188               | 3,496,526                    | 3,038,175                    | 2,810,191                    | 2,385,676                    |
| Current portion of long-term debt . . . . .   | 1,030,021               | 1,237,169                    | 1,023,312                    | 933,160                      | 5,114                        |
| Long-term debt (excluding current portion) . . . . .                                | 3,692                   | 3,788                        | 224,992                      | 763,097                      | 1,284,410                    |
| Accumulated deficit . . . . .   | (411,323)               | (633,871)                    | (432,578)                    | (579,087)                    | (406,364)                    |
| Stockholders' equity . . . . .  | <u>1,502,926</u>        | <u>1,292,324</u>             | <u>1,302,138</u>             | <u>603,156</u>               | <u>818,798</u>               |

\* As adjusted for the retrospective application of a change in accounting method for inventory. See Note 1 of the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for additional information.